Prisoners Treated for Hepatitis C with Protease Inhibitor, New York, USA, 2012
نویسندگان
چکیده
region have the potential to affect the rate of replication (8–10), it is possible that minor genome changes are responsible for the rapid spread and high severity of disease in 2014. Correlation between clinical features of patients in conjunction with additional genomic analysis might provide further insight into the pathogenetic determinants of this strain. Therefore the genome sequence of EV-D68 determined from the 2014 outbreak in St. Louis, Missouri, provides a resource for tracking and genomic comparison of this rapidly spreading virus.
منابع مشابه
boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
Department of Medicine, Division of Gastroenterology/ Hepatology, Indiana University School of Medicine, Indianapolis, IN, USA (P Y Kwo MD); Alamo Medical Research, San Antonio, TX, USA (E J Lawitz MD); Mount Vernon Endoscopy Center, Alexandria, VA, USA (J McCone MD); Divison of Hepatology, University of Miami, Miami, FL, USA (Prof E R Schiff MD); Departments of Medicine and Surgery, Baylor Col...
متن کاملPrevalence of Hepatitis B and C in Male Prisoners in Iranian Prisons
Introduction: Prison, as the most important place for the transmission of infectious diseases, has particular importance, and prison populations are at high risk for infectious diseases like Hepatitis B & C. This study aimed to determine the prevalence of Hepatitis B & C among male inmates in six prisons of different provinces in Iran in 2012. Methods: In...
متن کاملAdvances in the treatment of hepatitis C virus infection.
Since 2007, the annual age-adjusted mortality rate in hepatitis C virus (HCV) infection in the United States has been greater than that in HIV disease, reflecting the continuing decline in HIV-related mortality and the continuing increase in HCV-related mortality. The approval of 2 new direct-acting antivirals within the past year, as well as the promise offered by numerous other direct-acting ...
متن کاملBeyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection.
The addition of the hepatitis C virus (HCV) protease inhibitors telaprevir and boceprevir to peginterferon alfa with ribavirin therapy has increased cure rates in HCV infection. Numerous other direct-acting antivirals (DAAs) are in advanced stages of development, including next-generation protease inhibitors, nonstructural protein (NS) 5A inhibitors, and nonnucleoside and nucleos(t)ide NS5B pol...
متن کاملProtease inhibitor-based therapy for hepatitis C virus infection-why wait?
JSG The chance of clearing the virus and achieving a sustained virologic response (SVR) nearly doubled with the addition of these protease inhibitors. This improvement gave many people in the field of medicine a sense of renewal, as we finally have new agents to add to the interferon and ribavirin regimen that was the standard treatment for hepatitis C virus (HCV) infection for more than 10 years.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 21 شماره
صفحات -
تاریخ انتشار 2015